Physician profile
Pious Subedi
NPI 1265069231
$8,043.46
in general payments reported to CMS, 2019-2025
29 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $981 · 2022: $1,206 · 2023: $2,170 · 2024: $1,981 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,832 · Education: $24.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.88 |
| Education | $24.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,099.63 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Cumberland Pharmaceuticals, INC. | $909.68 | 2022-2025 | Vibativ |
| Paratek Pharmaceuticals, INC. | $720.44 | 2022-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $686.97 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $632.35 | 2021-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $547.35 | 2021-2025 | Biktarvy, Veklury |
| Shionogi INC | $401.83 | 2021-2025 | Fetroja |
| Melinta Therapeutics, LLC | $333.64 | 2023-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Janssen Biotech, INC. | $256.12 | 2021-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $231.02 | 2021-2025 | Zevtera |
| Abbvie INC. | $196.53 | 2021-2025 | |
| Boston Scientific Corporation | $154.68 | 2022-2024 | Watchman Access System |
| Medtronic, INC. | $137.66 | 2024 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $126.24 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $121.18 | 2024-2025 | Impella |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $100.63 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $99.33 | 2024-2025 | Vowst |
| Janssen Products, LP | $60.00 | 2021 | |
| Philips North America LLC | $39.03 | 2024-2025 | Vest Therapy Und, (Bo0) Hosp Vent Devices |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2023 | Hyqvia |
| Cormedix INC. | $25.22 | 2025 | Defencath |
| Theratechnologies INC. | $23.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.05 | 2022 | |
| Cashflow Solutions, LLC | $16.01 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Teleflex LLC | $13.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2024 | Eliquis |
| Pfizer INC. | $12.91 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $12.71 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pious Subedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.